Should IHS Holding's (IHS) Strong Q3 Earnings and 2025 Growth Outlook Prompt Investor Attention?

• IHS Holding Limited recently reported its third quarter 2025 earnings, highlighting sales of US$455.1 million and a net income of US$151 million, compared to a net loss in the same period last year, and also issued full-year guidance projecting approximately 10% organic revenue growth for 2025.
• This improvement in financial performance was primarily attributed to strong constant currency growth and operational gains, although the benefit from foreign exchange and power cost adjustments was revised downward due to updated currency and diesel price assumptions.
• We'll examine how IHS Holding's positive financial results and upgraded 2025 outlook may affect its investment narrative, especially as organic revenue growth strengthens.

We've found 14 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

IHS Holding Investment Narrative Recap

To own shares of IHS Holding, an investor has to believe in continued mobile data growth, robust wireless infrastructure demand, and the company’s ability to translate operational progress into consistent financial gains. The recent Q3 earnings and newly issued 2025 guidance solidify the case for organic revenue growth as a key short-term catalyst, yet persistent currency headwinds, especially in major markets like Nigeria, remain a serious risk to watch. While the FX impact was revised downward, this adjustment does not materially alter the main near-term risk profile for IHS, which centers on currency devaluation’s ability to offset dollar-reported growth. Among recent announcements, the Q3 2025 earnings report stands out most, highlighting a strong return to profitability with US$151 million net income versus a prior-year net loss. This significant improvement closely tracks with the company’s narrative that operational efficiency and demand fundamentals are translating into bottom-line results, underscoring the continued importance of local currency stability as a lever for future upside, or downside. Yet, even with operational momentum, the exposure to ongoing currency swings, especially unexpected moves in the Naira, is something every investor should be mindful of...

Read the full narrative on IHS Holding (it's free!)

IHS Holding is projected to reach $2.0 billion in revenue and $268.3 million in earnings by 2028. This outlook is based on anticipated annual revenue growth of 4.1% and an increase in earnings of $157.4 million from current earnings of $110.9 million.

Uncover how IHS Holding's forecasts yield a $9.66 fair value, a 40% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members supplied six fair value estimates for IHS Holding stock, ranging widely from US$9.66 to US$23.94 per share. While many expect continued operational improvement, the risk of emerging-market currency devaluation could still influence the company’s future performance in ways not yet reflected in these numbers.

Explore 6 other fair value estimates on IHS Holding - why the stock might be worth just $9.66!

Build Your Own IHS Holding Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your IHS Holding research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free IHS Holding research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate IHS Holding's overall financial health at a glance.

Seeking Other Investments?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• Find companies with promising cash flow potential yet trading below their fair value.
• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com